Risk factors

New disclosures detail reliance on Talicia Holding for Talicia manufacturing and emerging regulations for artificial intelligence in drug development. Pricing pressure risks were updated to incorporate the Trump Administration's drug pricing executive orders.

Clinical trial progress is highlighted with updates for drug candidates CRB-701, CRB-601, and CRB-913 across various phases. Personnel retention and stock option reliance are introduced as new operational risks. Financial disclosures updated to reflect $163.3 million in cash and investments for 2025.

Stablecoin confidence, redemption, reserve, and marketplace risks dominate the risk section.

Accumulated deficit increased to $56,588,218 as of December 31, 2025. Subcontractor performance is now tied directly to prime contractor agency relations.

Customer concentration shifted from one large client to two Healthcare Solutions clients representing 12.2% and 11.4% of revenue. Climate and weather supply chain disruptions were added as a new risk. Export control settlement obligations with BIS, DDTC, and ITAR were resolved.

New trade tariff risks were added alongside expanded discussions on healthcare legislation like the OBBBA and the ACA.

Federal infrastructure funding uncertainty threatens our reliance on government programs. Labor shortages and rising training costs threaten our labor-intensive operations. Goodwill impairment risks arise from potential downturns in customer demand and profitability.

Eagle Bancorp Montana added risks concerning ESG scrutiny, AI usage, and the OBBBA tax act.

Editas Medicine highlights preclinical reliance on EDIT-401, ongoing net losses totaling $1.6 billion, and risks from U.S. government shutdowns impacting FDA reviews.

Eagle Bancorp added risks regarding trade policy and tariffs while tightening disclosures on Washington D.C. real estate exposure and federal workforce reductions.

Tax credits and federal policies shifted, impacting EV adoption incentives and charging infrastructure funding.

AML/OFAC compliance is newly emphasized, including transaction screening, blocked transactions, reporting, and limits on acquisitions or branches.